MORRISTOWN, N.J., March 26 /PRNewswire/ -- Vicus Therapeutics, LLC, an
oncology-focused, clinical-stage, biopharmaceutical company, announced that
Navaneetha K. Rao, Vice President Clinical Research and Development, is
scheduled to present at Cambridge Healthtech Institute's 15th International
Molecular Medicine Tri-Conference on March 28st at 1:35 p.m. PST at the
Mascone North Convention Center in San Francisco. Dr. Rao will focus on
considerations that are particularly relevant to successfully executing a
Phase 2 multi-center study in India including:
-- Identification and management of clinical research organizations
-- Subject recruitment
-- Principal investigators and site management
-- Project management and communication
-- Quality management
About Vicus Therapeutics
Vicus Therapeutics is a privately-held, biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of cancer supportive care indications with an initial focus on cachexia. Vicus' lead combination product candidate, VT-122, is in Phase 2 clinical trials for the treatment of cancer cachexia in patients with advanced lung cancer. Additionally, Vicus has preclinical-stage combination product candidates being evaluated for the treatment of oral mucositis and cancer fatigue.
For additional information, go to the Company's website: http://www.vicustherapeutics.com.
|SOURCE Vicus Therapeutics, LLC|
Copyright©2008 PR Newswire.
All rights reserved